Yazarlar : Huynh M, Goßmann J, Klapper W et al

Yayın : Leuk Lymphoma

Yayın Yılı : 2014

Pubmed Linki : http://www.docguide.com/expression-and-pro-survival-function-phospholipase-c-gamma-2-diffuse-large-b-cell-lymphomas?tsid=5

Konu : Lenfoma

Literatür İçeriği :  Abstract Diffuse large B cell lymphomas can be cured in about 60% of cases with immuno-chemotherapy. However, a large subset of patients with DLBCL does not go into remission or relapse after first line therapy. Further therapy options are therefore needed. PLCgamma2 is one of the key regulators of the B cell receptor signaling pathway, which targets several pro-proliferative factors, such as NFkB, Ras and Akt. Using immunohistochemistry, we found that PLCgamma2 was strongly expressed in 63% of DLBCL cases. The PLC-inhibitor U73122 had inhibitory effect on cell proliferation, induced apoptosis and G0/G1 cell cycle arrest. Co-treatment with Enzastaurin or the Src-inhibitor pp2 together with U73122 had an additive effect on cell proliferation compared to U73122 alone. Unexpectedly, strong PLCgamma2 expression was associated with better overall survival. In conclusion, PLCgamma2 is strongly expressed in a significant number of DLBCL and has prognostic implications. Inhibition of PLCgamma2 could be a new target for lymphoma treatment.

Literatür Arşivi